VIDEO INTERVIEW – COVID 19 AND CARDIOVASCULAR DISEASES

Overview

COVID-19 infection has created a dramatic heath problem worldwide. In addition to respiratory distress, it became immediately apparent that patients with cardiovascular disease were at increased risk for a poor outcome or death from COVID-19. In addition, COVID-19 is able to act directly on cardiac tissue, provoking acute myocarditis. The situation is further complicated by the hypothesis that drugs acting on the renin-angiotensin system might worsen the prognosis in patients with COVID-19 because of the role of ACE2 in modulating cell penetration by the virus. Thus, there is need to discuss in detail the relationship between COVID-19 and cardiovascular disease, including the best therapeutic options to limit the negative cardiovascular consequences of the infection.

Learning Objectives

By viewing this video interview learners will:

  • Acquire information about the mechanisms underlying and responsible for the worsening of prognosis in COVID-19 patients with cardiovascular disease.
  • Examine the available evidence surrounding RAS-blocker administration and the severity of COVID-19 disease.
  • Discuss the best therapeutic approach for cardiovascular disease patients at risk of infection with COVID-19 virus.

Target audience

This activity is designed for Cardiologists, General Practitioners, Internists and those treating patients with cardiovascular disorders.

Faculty

Giuseppe Mancia
Professor Emeritus
University of Milano-Bicocca
Milan, Italy

Biography

Giuseppe Mancia is Professor Emeritus at the University Milano-Bicocca, Milan, Italy and Chairman of the European Society of Hypertension (ESH) Foundation and the Hypertension Center at the Monza Polyclinic, after serving as Chairman of the Department of Internal Medicine of Milano and Milano-Bicocca University, Monza for 20 years. He was Chairman of the Organizing Committee of ESH meetings for 20 years, and is a past President of the International Society of Hypertension (ISH), European Society of Clinical Investigation, and Italian Society of Hypertension. He has been Chairman of the European Society of Cardiology (ESC) Working Group on Hypertension and the Heart and chaired the ESH/ESC Hypertension Guidelines Task Force in 2003, 2007, 2009, 2013 and 2018. Professor Mancia is an honorary member of several hypertension and cardiovascular societies and has received many international awards and degrees honoris causa for his scientific activity. He is the Editor of the Journal of Hypertension. Professor Mancia’s research focuses on several basic and clinical aspects of hypertension and cardiovascular disease. He has published more than 2000 articles in peer review journals, and his articles have received more than 200,000 citations (Microsoft Academics), for which he is listed as a highly cited scientist.

Faculty Disclosure

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Giuseppe Mancia Declared receipt of honoraria or consultation fees from Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini, Merck, Novartis, Recordati, Sanofi, Servier.

All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation.

This independent educational activity is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.

Release: 15 October 2020

Copyright 2020 Scientific Seminars International Foundation